Effects of parenteral iron on inflammation and the myocardium in hemodialysis patients

Hemodialysis International

Volumn 12, Issue 3, 2008, Pages 362-368

  Sood, Manish M ^a   Oudit, Gavin Y ^a   Mohammadi, Hanif ^a   Huang, Hong ^a   Lok, Charmaine E ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Cardiac disease; Hemodialysis; Inflammation; Intravenous iron

Indexed keywords

FERRITIN; IRON; TRANSFERRIN;

ANEMIA; ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; DRUG EFFECT; ECHOCARDIOGRAPHY; ECHOGRAPHY; FEMALE; HEART DISEASE; HEART MUSCLE; HUMAN; IMMUNOLOGY; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PATHOLOGY; PILOT STUDY; RENAL REPLACEMENT THERAPY;

ANEMIA; ECHOCARDIOGRAPHY; FEMALE; FERRITINS; HEART DISEASES; HUMANS; INFLAMMATION; INJECTIONS, INTRAVENOUS; IRON; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; OXIDATIVE STRESS; PILOT PROJECTS; RENAL DIALYSIS; TRANSFERRIN;

EID: 55949107290     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2008.00282.x     Document Type: Article

References (44)

1. Fort J. Chronic renal failure: A cardiovascular risk factor. Kidney Int. 2005;68:(Suppl):S25-S29.
2. Perazella MA, Khan S. Increased mortality in chronic kidney disease: A call to action. Am J Med Sci. 2006; 331:150-153.
3. Locatelli F, Pozzoni P, Del Vecchio L. Anemia and heart failure in chronic kidney disease. Semin Nephrol. 2005; 25:392-396.
4. Yeo FE, Villines TC, Bucci JR, et al. Cardiovascular risk in stage 4 and 5 nephropathy. Adv Chronic Kidney Dis. 2004; 11:116-133.
5. Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors. JAMA. 2005; 293: 1737-1745.
6. Hsu CY, McCulloch CE, Curhan GC. Iron status and hemoglobin level in chronic renal insufficiency. J Am Soc Nephrol. 2002; 13:2783-2786.
7. Wingard RL, Parker RA, Ismail N, et al. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis. 1995; 25:433-439.
8. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995; 26:41-46.
9. Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996; 50: 1694-1699.
10. Beutler E. History of iron in medicine. Blood Cells Mol Dis. 2002; 29:297-308.
11. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol. 2004; 15(SUPPL 2):S93-S98.
12. Slotki I. Intravenous iron supplementation in the anaemia of renal and cardiac failure: A double-edged sword? Nephrol Dial Transplant. 2005; 20(Suppl 7): vii16-vii23.
13. Lim CS, Vaziri ND. The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure. Kidney Int. 2004; 65:1802-1809.
14. Shah SV, Alam MG. Role of iron in atherosclerosis. Am J Kidney Dis. 2003; 41:S80-S83.
15. Halliwell B, Chirico S. Lipid peroxidation: Its mechanism, measurement, and significance. Am J Clin Nutr. 1993; 57:715S-724S; discussion 724S-725S.
16. de Valk B, Marx JJ. Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med. 1999; 159:1542-1548.
17. Lim PS, Wei YH, Yu YL, et al. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant. 1999; 14:2680- 2687.
18. Wizemann V, Blank S, Kramer W. Diastolic dysfunction of the left ventricle in dialysis patients. Contrib Nephrol. 1994; 106:106-109.
19. London GM, Guerin AP, Marchais SJ. Pathophysiology of left ventricular hypertrophy in dialysis patients. Blood Purif. 1994; 12:277-283.
20. Parfrey PS, Harnett JD, Barre PE. The natural history of myocardial disease in dialysis patients. J Am Soc Nephrol. 1991; 2:2-12.
21. Shlipak MG, Fried LF, Stehman-Breen C, et al. Chronic renal insufficiency and cardiovascular events in theelderly: Findings from the cardiovascular health study. Am J Geriatr Cardiol. 2004; 13:81-90.
22. Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int. 2003; 63:1121-1129.
23. Zager RA, Johnson AC, Hanson SY, et al. Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis. 2002; 40:90-103.
24. Fishbane S. Safety in iron management. Am J Kidney Dis. 2003; 41:18-26.
25. Eaton JW, Qian M. Molecular bases of cellular iron toxicity. Free Radic Biol Med. 2002; 32:833-840.
26. Oudit GY, Trivieri MG, Khaper N, et al. Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron-overload murine model. Circulation. 2004; 109:1877-1885.
27. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991; 11:81-128.
28. Lee SH, Oe T, Blair IA. Vitamin C-induced decomposition of lipid hydroperoxides to endogenous genotoxins. Science. 2001; 292:2083-2086.
29. 2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med. 2003; 9:1187-1194.
30. Kadiiska MB, Burkitt MJ, Xiang QH, et al. Iron supplementation generates hydroxyl radical in vivo: An ESR spin-trapping investigation. J Clin Invest. 1995; 96:1653- 1657.
31. Young IS, Trouton TG, Torney JJ, et al. Antioxidant status and lipid peroxidation in hereditary haemochromatosis. Free Radic Biol Med. 1994; 16:393-397.
32. Livrea MA, Tesoriere L, Pintaudi AM, et al. Oxidative stress and antioxidant status in beta-thalassemia major: Iron overload and depletion of lipid-soluble antioxidants. Blood. 1996; 88:3608-3614.
33. Lim PS, Chan EC, Lu TC, et al. Lipophilic antioxidants and iron status in ESRD patients on hemodialysis. Nephron. 2000; 86:428-435.
34. Bhatnagar A. Electrophysiological effects of 4-hydroxynonenal, an aldehydic product of lipid peroxidation, on isolated rat ventricular myocytes. Circ Res. 1995; 76: 293-304.
35. Nakaya H, Tohse N, Kanno M. Electrophysiological derangements induced by lipid peroxidation in cardiac tissue. Am J Physiol. 1987; 253:H1089-H1097.
36. Folden DV, Gupta A, Sharma AC, et al. Malondialdehyde inhibits cardiac contractile function in ventricular myocytes via a p38 mitogen-activated protein kinasedependent mechanism. Br J Pharmacol. 2003; 139:1310- 1316.
37. Horackova M, Ponka P, Byczko Z. The antioxidant effects of a novel iron chelator salicylaldehyde isonicotinoyl hy-drazone in the prevention of H(2)O(2) injury in adult cardiomyocytes. Cardiovasc Res. 2000; 47:529-536.
38. Schwartz KA, Li Z, Schwartz DE, et al. Earliest cardiac toxicity induced by iron overload selectively inhibits electrical conduction. J Appl Physiol. 2002; 93:746-751.
39. Drueke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002; 106:2212-2217.
40. Kuryshev YA, Brittenham GM, Fujioka H, et al. Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes: Implications for the arrhythmogenesis of human siderotic heart disease. Circulation. 1999; 100:675-683.
41. Buja LM, Roberts WC. Iron in the heart: Etiology and clinical significance. Am J Med. 1971; 51:209- 221.
42. Wu VC, Huang JW, Wu MS, et al. The effect of iron stores on corrected QT dispersion in patients undergoing peritoneal dialysis. Am J Kidney Dis. 2004; 44: 720-728.
43. Mariotti E, Agostini A, Angelucci E, et al. Cardiac study by dobutamine stress echocardiography in thalassemic patients. Bone Marrow Transplant. 1993; 12(Suppl 1): 14-15.
44. Mavrogeni SI, Gotsis ED, Markussis V, et al. T2 relaxation time study of iron overload in b-thalassemia. MAGMA. 1998; 6:7-12.